ProMIS Neurosciences, Inc. PMN
Set alert
At close · Oct 30
After hours · Oct 30, 7:53 PM ET
- YTD
- -51.54%
- 1 year
- -68.48%
- Open
- 8.41
- Prev close
- 11.08
- Mkt cap
- 29.68M
- Vol
- 1.64M
- Avg vol
- 58.52K
- EPS
- -11.65
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.24
- High
- 8.42
- Forward P/E
- -1.51
- Beta
- 0.61
- Short ratio
- 2.64
- Inst. own
- 50.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.9886
- 200-d avg
- 1.51
- 1y target
- 7.65
5D chart
Signals (42)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 4:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:40 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:50 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:35 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:35 PM | 4 days ago |
| RSI: Overbought | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:50 PM | 6 days ago |
News
2 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
2 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
3 days ago zacks.com
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development…
3 weeks ago globenewswire.com
ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer's clinical development, launch readiness, commercialization and global medical strategy
2 months ago globenewswire.com
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.
2 months ago marketbeat.com
Promis Neurosciences Q2 Earnings Call Highlights
Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for…
-
2 months ago benzinga.com
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs.…
-
2 months ago benzinga.com
ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of…
2 months ago globenewswire.com
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody…
3 months ago gurufocus.com
Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum
Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year.CF Revenue: Global CF revenue grew 11% year-over-year in Q2 2026.CASGEVY Revenue: $76 million in Q
3 months ago globenewswire.com
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Company to host investor conference call and webcast at 4:30 p. m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.
-
3 months ago benzinga.com
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $35 to $69.
3 months ago marketbeat.com
Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data
Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out…
3 months ago benzinga.com
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
ProMIS Neurosciences Inc. (NASDAQ:PMN) reported positive blinded six-month interim safety and biomarker results from its ongoing Phase 1b PRECISE-AD trial evaluating lead drug candidate PMN310 in…
3 months ago benzinga.com
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.
-
3 months ago benzinga.com
Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33
Chardan Capital analyst Keay Nakae maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $20 to $33.
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…
-
3 months ago benzinga.com
Market-Moving News for July 28th
AMKR: -9% | Amkor Technology shares are trading lower after the company reported Q2 financial results and issued Q3 sales guidance below estimates. PMN: 32% | ProMIS Neurosciences shares are trading…
-
3 months ago benzinga.com
ProMIS Neurosciences Announces Six-Month Interim Safety And Biomarker Results From Its PRECISE-AD Phase 1B Trial Of PMN310 In Patients With Mild Cognitive Impairment Due To Alzheimer’s; Early Biomarker Movement Consistent With Target Engagement
In the blinded interim analysis evaluating 136 AD patients, PMN310 was observed to have a favorable safety profile across all genotypes, with no cases of amyloid-related imaging abnormalities-edema…
3 months ago globenewswire.com
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in…
3 months ago benzinga.com
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
3 months ago globenewswire.com
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting…
-
3 months ago benzinga.com
Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20
Chardan Capital analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $20.
-
3 months ago benzinga.com
ProMIS Neurosciences' PMN310 Shows Dose-Dependent Reduction Of Amyloid-Beta Oligomers In Healthy Volunteers, With Six-Month Phase 1b Interim Data Expected Soon
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteersRepresents one of the first quantitative measures of…
3 months ago globenewswire.com
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of…
-
3 months ago benzinga.com
Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $19.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings…
4 months ago zacks.com
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 230.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
-
4 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On ProMIS Neurosciences with Overweight Rating
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Overweight rating.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
4 months ago zacks.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy
Promis Neurosciences (PMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
4 months ago zacks.com
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 231.8% in Promis Neurosciences (PMN). While the effectiveness of this highly sought-after metric is…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
5 months ago gurufocus.com
GMG Applies for Additional Environmental Approvals to Produce Graphene in USA
BRISBANE, AUS, June 2, 2026 - (ACN Newswire) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that
5 months ago gurufocus.com
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f
-
5 months ago benzinga.com
ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the analyst consensus estimate of $(1.48) by 14.86 percent. This is a 76 percent increase over losses of…
-
7 months ago benzinga.com
CORRECTION: ProMIS Neurosciences Q4 EPS $(3.11) Misses $(0.21) Estimate
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(3.11) per share which missed the analyst consensus estimate of $(0.21) by 1380.95 percent. This is a 522 percent decrease over losses…
-
7 months ago benzinga.com
ProMIS Neurosciences To Highlight Data On ALS & Parkinsons Disease Programs At AD/PD 2026 International Conference
ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
8 months ago benzinga.com
Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $35
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $125 to $35.
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session